How can we regulate medicines better?

Abstract

Agency's role The agency gives opinions on the quality, safety, and efficacy of new drugs that manufacturers want to market in the European Union. The European Commission uses the agency's opinions to decide whether to grant a licence. Unlike the US Food and Drug Administration, the European agency is not autonomous but an expression of the national agencies in the European Union, which approve most new products. Evaluation through the centralised procedure has become mandatory for biotechnology products and drugs for HIV, cancer, neurovegetative disorders, diabetes, rare diseases, the autoimmune system, and viral diseases. The European agency is important because central authorisation is increasing and because national agencies cannot justify adopting methods and criteria inconsistent with those of the central agency. When national agencies come to differing decisions, the European agency makes a final decision that is binding in all member states.